United States mRNA Vaccine and Therapeutics Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

mRNA Vaccines and Therapeutics market size reached US$ 46.32 Billion in 2024 and is expected to reach US$ 200.11 Billion by 2033, growing at a CAGR of 18.4% during the forecast period 2025-2033.

Key Development:

United States: Recent Industry Developments

✅ July 30, 2025: Dx&Vx entered into a co-development and license agreement valued at approximately USD 220 million with a U.S.-based company to advance mRNA vaccine and therapeutic candidates.

✅ July 18, 2025: Moderna canceled plans to build a new mRNA manufacturing plant in Japan due to unfavorable global and domestic business conditions, including declining revenue from COVID-19 vaccines and regulatory challenges.

✅ August 5, 2025: The U.S. Department of Health and Human Services (HHS) announced the termination of 22 mRNA vaccine development projects under the Biomedical Advanced Research and Development Authority (BARDA), reallocating approximately $500 million in funding to alternative vaccine platforms.

Japan: Recent Industry Developments

✅ September 19, 2025: Japanese biotech xFOREST Therapeutics partnered with a drug discovery solutions provider to develop new RNA structure-targeted small molecule therapeutics, including mRNA candidates, expanding the country's mRNA research landscape.

✅ June 23, 2025: Moderna filed for approval of mRNA-1283, a next-generation COVID-19 vaccine optimized for refrigerated storage, aiming to enhance distribution efficiency in Japan.

✅ May 2025: Moderna's mRNA-1345, an RSV vaccine for older adults, received approval in Japan, marking a significant step in expanding mRNA vaccine applications beyond COVID-19.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/mrna-vaccine-and-therapeutics-market?sb

Recent Mergers and acquisitions :

United States: Recent M&A Developments

✅ August 14, 2025: CureVac announced a settlement with GSK, agreeing to an upfront payment of $370 million. Additionally, GSK will receive a 1% royalty on future Pfizer/BioNTech U.S. sales of influenza, COVID-19, and related combination mRNA vaccine products.

✅ August 7, 2025: Strand Therapeutics, a U.S.-based mRNA therapeutics company, closed a $153 million Series B funding round. The investment will support the advancement of its pipeline of novel mRNA therapies for cancer and other chronic conditions, including its lead asset, STX-001, an intra-tumor self-replicating mRNA therapy.

✅ July 22, 2025: Sanofi announced the acquisition of Vicebio Ltd, a privately held biotechnology company based in London, UK. The acquisition aims to expand Sanofi's respiratory vaccines pipeline, bringing in an early-stage combination vaccine candidate for RSV and hMPV, utilizing Vicebio's 'Molecular Clamp' technology.

Key Players:

=> Azra Al, CureMetrix, Inc., ConcertAI, Immunai, MVision AI Inc., Paige AI, Inc., Mindpeak GmbH, Imagene AI Ltd., Predictive Oncology, and Tempus, among others.

Growth Forecast Projected:

The Global mRNA Vaccine and Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2033. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global mRNA Vaccine and Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=mrna-vaccine-and-therapeutics-market

Key Segments:

➥ By Product Type: Prophylactic Vaccines, Therapeutic Vaccines, Therapeutic Drugs

➥ By Application: Cancer, Infectious Diseases, Rare Genetic Diseases, Others

➥ By End-User: Hospitals & Clinics, Research Organizations, Academic Institutes, Others

Regional Analysis for mRNA Vaccine and Therapeutics Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among mRNA Vaccine and Therapeutics producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze mRNA Vaccine and Therapeutics revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/mrna-vaccine-and-therapeutics-market?sb

FAQ

What is the current size of the mRNA Vaccine and Therapeutics Market?

A: In 2024, the mRNA Vaccine and Therapeutics Market was valued at US$ 46.32 Billion, reflecting its strong industry presence.

Q2: How large is the mRNA Vaccine and Therapeutics Market expected to be by 2033?

A: By 2033, industry forecasts suggest the mRNA Vaccine and Therapeutics Market will grow to around US$ 200.11 Billion , demonstrating significant expansion.

Q3: What is the growth rate of the mRNA Vaccine and Therapeutics Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 18.4% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.